The HSPG2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HSPG2 gene in the human A-549 lung epithelial cell line. This population results from bulk gene disruption and lacks clonal selection, providing a heterogeneous knockout model suitable for investigating perlecan function without the biases of single-cell cloning. The polyclonal format enables researchers to assess population-level effects of HSPG2 loss on cellular phenotypes.
The A-549 cell line is derived from human lung adenocarcinoma and exhibits epithelial morphology. It is widely used as a model for human alveolar type II epithelium, making it a standard platform in cancer biology, drug metabolism, and respiratory disease research. Its well-characterized growth properties and responsiveness to external stimuli support reproducible functional studies.
HSPG2 encodes perlecan, a major heparan sulfate proteoglycan of basement membranes. Perlecan modulates cell adhesion, proliferation, and differentiation through interactions with integrins (e.g., ??2??1, ??V??3) and by sequestering growth factors such as FGF2 and VEGFA via its heparan sulfate chains. This facilitates presentation to cognate receptors (FGFR1, VEGFR2), activating ERK and AKT signaling cascades. Upstream regulators include TGFB1, HIF1A, and inflammatory cytokines like IL1B, while downstream effects encompass ECM organization and angiogenesis promotion.
In A-549 cells, perlecan contributes to the malignant phenotype by supporting anchorage-independent growth, invasion, and resistance to apoptosis. Loss of HSPG2 in this context disrupts basement membrane integrity and growth factor signaling networks, providing a useful model to dissect the molecular underpinnings of tumor progression and metastasis. The polyclonal knockout population allows assessment of heterogeneous responses to perlecan deficiency, reflecting the complexity of tumor cell populations.
Typical applications include tube formation assays to evaluate angiogenesis, Boyden chamber migration/invasion studies, cell adhesion assays, and western blot analysis of phospho-ERK and phospho-AKT levels. Additionally, this model supports drug screening for anti-metastatic compounds and mechanistic studies of growth factor signaling. Researchers can also employ co-immunoprecipitation to examine perlecan??s interacting partners, such as laminin and collagen IV. For further information, please contact Ascent Research.
